Head and Neck Squamous Cell Carcinoma research hub

Thermotherapy in Addition to SOC Palliative Radiotherapy

This study looks at adding a gentle heat treatment (thermotherapy) to standard radiotherapy for certain advanced or recurrent head, neck, skin, or breast cancers. It aims to see if this combination is safe and helps shrink tumours more effectively for patients in the UK.

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

This study looks at a new drug, evorpacept, combined with pembrolizumab and chemotherapy for advanced head and neck cancer. It aims to see if this new combination is effective for patients who haven't had treatment for their advanced disease.

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

This study is testing a new drug, OKN4395, alone and with an existing cancer treatment, pembrolizumab, for various solid tumours. The main goals are to check its safety, how well it's tolerated, and if it helps fight cancer.

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

This study is looking at a new drug called MCLA-158 for advanced cancers like bowel and head and neck cancer. It aims to find the safest dose and see how well it works alone or with other treatments. It's for patients whose cancer has spread or come back.

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

This study is looking at a new treatment called tislelizumab, sometimes combined with other medicines, for head and neck cancer that has come back or spread. The aim is to see if it can shrink tumours and if it's safe for patients.

Liquid Biopsy for Early DiagNosis of Squamous Cell Carcinoma of the HeAd and NeCk rEgion

This study is looking into a new, simple blood test called a "liquid biopsy" to help find head and neck cancer earlier. By checking tiny bits of DNA in your blood, doctors hope to speed up diagnosis, helping people get treatment sooner and potentially improving their chances of recovery.

A Study of NX-1607 in Adults With Advanced Malignancies

This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

This study compares a new treatment combining petosemtamab and pembrolizumab with pembrolizumab alone for advanced head and neck cancer. It aims to see if the combination works better and is safe for patients whose cancer has come back or spread.

Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

This study is testing new combinations of treatments for head and neck cancer that has come back or spread. It compares two new drugs plus chemotherapy against one new drug plus chemotherapy. The aim is to find safer and more effective ways to treat this type of cancer.

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This study is looking at a new treatment called petosemtamab for advanced head and neck cancer. It compares this new drug with standard treatments chosen by doctors, for patients whose cancer has come back or spread after previous therapies.

A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

This study is for adults with head and neck cancer that has spread or returned. It tests if combining new medicines like BI 770371, pembrolizumab, and cetuximab can shrink tumors better than pembrolizumab alone. It aims to see if these combinations help the immune system fight cancer.

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

This study is for people with head and neck cancer that has come back or spread and can't be cured by usual treatments. It compares a new drug, zanzalintinib, combined with pembrolizumab, against pembrolizumab alone, to see if the new combination works better.

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

This study is testing a new drug, LY4052031, for people with advanced cancers like bladder, breast, and lung cancer. It aims to see if the drug is safe, what dose works best, and if it helps shrink tumors. It's an early-stage study to gather important information.

A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)

This study is testing a new combination treatment, Ficerafusp Alfa and Nivolumab, for a type of head and neck cancer. It's for patients whose cancer has come back or worsened after previous treatments. Researchers want to see how well this new treatment shrinks the cancer.

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

This study looks at a new drug, evorpacept, combined with an existing one, pembrolizumab, for advanced head and neck cancer. It aims to see if this combination works better than pembrolizumab alone for patients who haven't had treatment for advanced stages of their cancer. It's a Phase 2 trial, meaning it's still in earlier stages of testing.

A Phase 1 Study of PRT3789 in Participants with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 1b, Open-Label, Dose-Escalation Trial of the Safety of and Antigen-Specific Immune Responses Elicited by VB.10 NEO in Combination With Atezolizumab in Subjects with Locally Advanced and Metastatic Tumors